Using network biology to find new uses for existing Alzheimer's drugs
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease
This study is looking at ways to use already-approved medications to help people with late-onset Alzheimer's disease by understanding how these drugs can work better in the brain to improve symptoms and possibly slow down the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10849845 on NIH RePORTER |
What this research studies
This research focuses on Alzheimer's disease, particularly late-onset Alzheimer's, which is the most common form of dementia. The team aims to discover new therapeutic uses for FDA-approved drugs by employing innovative network biology approaches that analyze complex interactions within biological systems. By integrating large-scale data, the research seeks to identify key molecular pathways involved in Alzheimer's and how existing drugs can target these pathways effectively. This could lead to more effective treatments that not only alleviate symptoms but also potentially modify the disease's progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with late-onset Alzheimer's disease.
Not a fit: Patients with early-onset Alzheimer's or other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve the quality of life for Alzheimer's patients.
How similar studies have performed: Previous research using network biology approaches has shown promise in repositioning drugs for other diseases, suggesting potential success in this novel application for Alzheimer's.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Zhang, Bin — Icahn School of Medicine at Mount Sinai
- Study coordinator: Zhang, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.